SCHEMBL3358857

SCHEMBL3358857

Fc1ccc(-c2nc3ccc(N4CCN5CCCC5C4)nn3c2-c2ccnnc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 6/20 0.63
ENPP2 Q13822 10/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3357408 0.94 CSNK1E (0.72) CSNK1EENPP2
SCHEMBL3115538 0.90 CSNK1E (0.78) CSNK1EENPP2
SCHEMBL3356959 0.90 CSNK1E (0.68) CSNK1EENPP2
SCHEMBL3358558 0.88 CSNK1E (0.81) CSNK1EENPP2
SCHEMBL3118585 0.83 CSNK1E (0.58) CSNK1EENPP2
SCHEMBL3106595 0.83 CSNK1E (0.91) CSNK1EENPP2
SCHEMBL3356106 0.81 CSNK1E (0.56) CSNK1E
SCHEMBL3115843 0.81 CSNK1E (0.84) CSNK1E
SCHEMBL3357875 0.80 CSNK1E (0.68) CSNK1EENPP2
SCHEMBL3355873 0.80 CSNK1E (0.81) CSNK1EENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108971-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof SANOFI (FR) 2015-08-18 US claimed
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI (FR) 2013-09-19 US claimed
EP-2178879-B1 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2013-07-03 EP claimed
US-8455491-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same SANOFI (FR) 2013-06-04 US claimed
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-06-17 US claimed
US-9108971-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof SANOFI (FR) 2015-08-18 US disclosed
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI (FR) 2013-09-19 US disclosed
EP-2178879-B1 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2013-07-03 EP disclosed
US-8455491-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same SANOFI (FR) 2013-06-04 US disclosed
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF TLR7, IFNAR1, CBR3 CSNK1E 757/4885ENPP2 1332/4885
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF IFNAR1, TLR7, CBR3 CSNK1E 724/4885ENPP2 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.